Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125260101 | 12526010 | 1 | I | 20160609 | 20160614 | 20160705 | 20160705 | EXP | IT-AMGEN-ITACT2016077137 | AMGEN | 68.00 | YR | E | M | Y | 0.00000 | 20160705 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125260101 | 12526010 | 1 | PS | carfilzomib | CARFILZOMIB | 1 | Intravenous (not otherwise specified) | 56 MG/M2, PER CHEMO REGIM | Y | 202714 | 56 | MG/M**2 | INTRAVENOUS INFUSION | ||||||
| 125260101 | 12526010 | 2 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 20 MG, PER CHEMO REGIM | Y | 0 | 20 | MG | UNKNOWN FORMULATION | ||||||
| 125260101 | 12526010 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Oral | 200 MG/M2, PER CHEMO REGIM | Y | 0 | 200 | MG/M**2 | UNKNOWN FORMULATION | ||||||
| 125260101 | 12526010 | 4 | C | ALLOPURINOL. | ALLOPURINOL | 1 | 300 MG, QD | 0 | 300 | MG | TABLET | QD | |||||||
| 125260101 | 12526010 | 5 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | UNK | 0 | |||||||||||
| 125260101 | 12526010 | 6 | C | ACYCLOVIR. | ACYCLOVIR | 1 | 400 MG, 8 AND 20 HOURS | 0 | 400 | MG | |||||||||
| 125260101 | 12526010 | 7 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | UNK,Q16H | 0 | CAPSULE | ||||||||||
| 125260101 | 12526010 | 8 | C | MYCOSTATIN | NYSTATIN | 1 | UNK | 0 | |||||||||||
| 125260101 | 12526010 | 9 | C | ZOMETA | ZOLEDRONIC ACID | 1 | 4 MG, UNK | 0 | 4 | MG | |||||||||
| 125260101 | 12526010 | 10 | C | CACIT D3 | CALCIUMCHOLECALCIFEROL | 1 | UNK UNK, QD | 0 | QD | ||||||||||
| 125260101 | 12526010 | 11 | C | BRETARIS GENUAIR | ACLIDINIUM BROMIDE | 1 | UNK UNK, BID | 0 | BID | ||||||||||
| 125260101 | 12526010 | 12 | C | ABRIFF | 2 | 125 UNK, BID | 0 | BID | |||||||||||
| 125260101 | 12526010 | 13 | C | PRONTINAL | BECLOMETHASONE DIPROPIONATE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125260101 | 12526010 | 1 | Plasma cell myeloma |
| 125260101 | 12526010 | 2 | Plasma cell myeloma |
| 125260101 | 12526010 | 3 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125260101 | 12526010 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125260101 | 12526010 | Bronchitis | |
| 125260101 | 12526010 | Respiratory failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125260101 | 12526010 | 1 | 20160421 | 20160606 | 0 | |
| 125260101 | 12526010 | 2 | 20160421 | 20160606 | 0 | |
| 125260101 | 12526010 | 3 | 20160421 | 20160523 | 0 | |
| 125260101 | 12526010 | 9 | 20160421 | 0 |